WT1 and neoplasm: Because the expression level of the WT1 gene is correlated with the tumor burden, detection of WT1 gene expression has been used for tracking ofminimal residual disease (MRD), early relapse, or disease progression during and after therapy against myeloid neoplasms, especially acute myeloid leukemia and myelodysplastic syndrome.[11,12] Further, Szanto et al. have reported high WT1 expression levels were seen in all acceleration phase (AP) and blast phase (BP) patients, and the data showed a statistically significant correlation.[13]